Wirksamkeit und Sicherheit von Cannabisarzneimitteln: Ergebnisse der CaPRis-Studie

Hoch, Eva; Friemel, Chris Maria; Schneider, Miriam; Pogarell, Oliver; Hasan, Alkomiet; Preuss, Ulrich W.; CaPRis-Projektgruppe,

doi:10.1007/s00103-019-02965-3

Cited by 13 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Medical cannabis has shown promising results in treating chronic pain, cancer, nausea, vomiting, appetite increase, spasticity and paraplegia in multiple sclerosis, weight gain, mental illness, autoimmune diseases, neurodegenerative diseases, and gastrointestinal disorders [16].…”

Section: Introductionmentioning

confidence: 99%

Cannabis use of patients with inflammatory bowel disease in Germany: a cross-sectional survey

et al. 2021

View full text Add to dashboard Cite

Background and Aims Progressive legalization and increasing utilization of medical cannabis open up potential new applications, including for inflammatory bowel disease (IBD). This study aimed to collect current figures on the use of and experience with cannabis among IBD patients in Germany. Methods A 71-item questionnaire was mailed to a randomly selected representative sample of 1000 IBD patients. Results Questionnaires were returned by 417 patients (mean age 49.1 ± 17.0 years; 55.8 % women; 43.4 % ulcerative colitis and 54.7 % Crohn’s disease). Seventy-three respondents (17.5 %) stated past cannabis use for recreational purposes, while 12 users mentioned usage at the time the questionnaire was completed (2.9 %). Seventeen patients (4.1 %) indicated past use of cannabis, and 18 participants (4.3 %) reported current use of cannabis to treat IBD. Perceived benefits of cannabis use by its users included reduced abdominal pain, improved sleep quality, and relief of unease and worry. They reported lower quality of life and higher levels of anxiety or depression than non-users. Of notice, 52.9 % of cannabis users obtained their cannabis from the black market. A total of 76.5 % of former and 50 % of current users did not report their cannabis use to the physician. Conclusion This survey reveals the largest data set on cannabis use among IBD patients in Germany, with the potential for further research. Cannabis is mainly procured from the black market, with unknown quality.

show abstract

Section: Introductionmentioning

confidence: 99%

Cannabis use of patients with inflammatory bowel disease in Germany: a cross-sectional survey

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Eine neue Meta-Analyse im Auftrag des Bundesministeriums für Gesundheit fasst systematisch die Ergebnisse von mehr als 2100 Einzelstudien zusammen, die die Wirkungen des Cannabisgebrauchs untersucht haben [2][3][4]. Gut belegt sind danach die vielfältigen gesundheitlichen Risiken, die mit dem Konsum von Cannabis verbunden sein können.…”

Section: Hintergrundunclassified

Prädiktoren und Auswirkungen von Ermittlungsverfahren wegen Cannabis

2020

View full text Add to dashboard Cite

Zusammenfassung Hintergrund und Zielsetzung 2018 wurden 218 660 Fälle von Rauschgiftkriminalität im Zusammenhang mit Cannabis registriert. Prädiktoren und Auswirkungen cannabisbezogener Ermittlungsverfahren sollten untersucht werden. Methode Retrospektive Kohortenstudie mit 10 432 Personen zwischen 15 und 46 Jahren (M=22,2 Jahre, SD=4,8); davon 54,6% männlich. Die Stichproben-Rekrutierung erfolgte 2018 über soziale Medien. Der Online Fragebogen erfasste potentielle Prädiktoren und als Ergebnisparameter die mentale Gesundheit, den sozialen Status, die Arbeitslosigkeit, die Höhe des Einkommens sowie problematischen Cannabis- und Alkoholkonsum. Ergebnisse 9246 Personen (88,6%) hatten jemals in ihrem Leben Cannabis konsumiert. Gegen 1736 Personen (18,8%) wurde ein cannabisbezogenes Ermittlungsverfahren eingeleitet. Diese Personen waren häufiger männlich, älter, verfügten seltener über das Abitur, hatten höhere Sensation Seeking-Werte, hatten häufiger eine ADHS-Diagnose, begannen früher mit dem Cannabiskonsum und hatten in allen Cannabiskonsumvariablen höhere Ausprägungen. Keine signifikanten Assoziationen fanden sich zwischen Ermittlungsverfahren und der Höhe des Einkommens, der Arbeitslosigkeit, der mentalen Gesundheit oder dem subjektiven sozialen Status. Von den befragten Nie- oder ehemaligen Konsumenten gaben 63,4 bzw. 44,8% als Grund für die Abstinenz an, keine Schwierigkeiten mit dem Gesetz bekommen zu wollen. Schlussfolgerung Es fanden sich keine Hinweise, dass cannabisbezogene Ermittlungsverfahren Auswirkungen auf die aktuelle Lebens- bzw. Gesundheitssituation hatten. Befürchtungen, Schwierigkeiten mit dem Gesetz zu bekommen, waren insbesondere für Personen relevant, die noch nie oder derzeit kein Cannabis konsumierten.

show abstract

“…Previous studies show a substantial improvement in 35.5% and a moderate improvement in 34.2% of patients treated [ 10 ]. Other common indications include spasticity in multiple sclerosis, nausea in patients with cancer, and specific mental health symptoms [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Patient Experiences With Prescription Cannabinoids in Germany: Protocol for a Mixed Methods, Exploratory, and Anonymous Web-Based Survey

Fischer¹,

Kandil²,

Karst³

et al. 2023

JMIR Res Protoc

View full text Add to dashboard Cite

Background Medical cannabinoids are controversial. Their use is comparatively rare, but it is rising. Since 2017, cannabinoids can be prescribed in Germany for a broader range of indications. Patient surveys on these drugs are hampered by the stigmatization of cannabinoids and their (still) low prevalence in medical contexts. Against this background, patients’ willingness to provide information is limited. Moreover, it is logistically challenging to reach them with a survey. A thorough knowledge of currently ongoing therapies and their effects and side effects, however, is important for a more appropriate and effective use of cannabinoids in the future. Objective This study is an exploratory data collection using a representative sample. The main goal is to provide a detailed picture of the current use of medical cannabinoids in Germany. It is intended to identify subgroups that may benefit particularly well or poorly. Methods We are conducting a representative, anonymous, cross-sectional, one-time, web-based survey based on mixed methods in 3 German federal states. Health conditions under cannabinoid therapy and before are documented with validated, symptom-specific questionnaires. This allows an estimation of the effect sizes of these therapies. The selection of parameters and questionnaires was based on the results of independent qualitative interviews in advance. Representative samples of the hard-to-reach study population are obtained by cluster sampling via contracted physicians of the statutory health insurance companies. Results Recruitment was ongoing until the end of June 2022, with 256 enrolled participants. Validated questionnaires on pain, spasticity, anorexia or wasting, multiple sclerosis, nausea or vomiting, depression, and attention deficit hyperactivity disorder (ADHD) were selected. Symptom scores are being assessed for both current conditions under cannabinoid therapy and conditions prior to this therapy (in retrospect). Validated questionnaires are also used for treatment satisfaction and general quality of life. These are supplemented by existing diagnoses, a detailed medication history, any previous experiences with cannabis or illegal substances, experiences with the prescription process, and sociodemographic data. Based on the results of the previous qualitative interviews, questions were added regarding prior experience with relaxation methods and psychotherapy, personal opinions about cannabinoids, pre-existing or symptom-related psychological trauma, and different experiences with different cannabis-based therapies. Conclusions The exploratory mixed methods approach of this project is expected to provide valid and relevant data as a basis for future clinical research. The study design may be representative for a large proportion of outpatients treated with cannabinoids in the German federal states studied. It may have less bias toward social desirability and may provide valuable information in addition to existing studies. Due to the observational and cross-sectional nature of this study, various limitations apply. Causal relations cannot be drawn. Trial Registration German Clinical Trials Register DRKS00023344; https://drks.de/search/en/trial/DRKS00023344 International Registered Report Identifier (IRRID) DERR1-10.2196/38814

show abstract

Wirksamkeit und Sicherheit von Cannabisarzneimitteln: Ergebnisse der CaPRis-Studie

Cited by 13 publications

References 17 publications

Cannabis use of patients with inflammatory bowel disease in Germany: a cross-sectional survey

Cannabis use of patients with inflammatory bowel disease in Germany: a cross-sectional survey

Prädiktoren und Auswirkungen von Ermittlungsverfahren wegen Cannabis

Patient Experiences With Prescription Cannabinoids in Germany: Protocol for a Mixed Methods, Exploratory, and Anonymous Web-Based Survey

Contact Info

Product

Resources

About